Md Ariful Haque

3.9k citations
75 papers · 2.6k · 2 hit papers · h-index 18

Impact in

  • Hematology top 0.2%
    • Chronic Myeloid Leukemia Treatments
    • Acute Myeloid Leukemia Research
  • Genetics top 0.2%
    • Chronic Lymphocytic Leukemia Research
    • Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

  • Genetics 36
    • Chronic Lymphocytic Leukemia Research 33
    • Myeloproliferative Neoplasms: Diagnosis and Treatment 6
  • Hematology 35
    • Chronic Myeloid Leukemia Treatments 33
Co-authors
Hagop M. Kantarjian (28 shared papers)Andreas Hochhaus (23 shared papers)Neil J. Gallagher (23 shared papers)Timothy P. Hughes (11 shared papers)Giuseppe Saglio (11 shared papers)Dong‐Wook Kim (11 shared papers)Richard A. Larson (12 shared papers)Albert Hoenekopp (3 shared papers)
Journals
Blood (21 papers)Journal of Clinical Oncology (11 papers)International Journal of Surgery (1 paper)Medicine (1 paper)Journal of Affective Disorders (1 paper)
Partner nations
ChinaUnited StatesGermany

In The Last Decade

Md Ariful Haque

59 papers receiving 2.6k citations

Md Ariful Haque's Hit Papers

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia 2010 · 1.2k citations
1.2k0+6+12Years since publication2505007501000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2010 New England Journal of Medicine
  2. 2007 Blood

Peers

Md Ariful Haque
Comparison fields: 5 of 105
  • Hematology 2.3k
  • Genetics 2.0k
  • Rheumatology 1.4k
  • Oncology 313
  • Pathology and Forensic Medicine 177
Replace Fausto Castagnetti with:
Fausto Castagnetti Italy
Valentín García‐Gutiérrez Spain
Sebastian Kreil Germany
Jamshid S. Khorashad United Kingdom
David T Yeung Australia
Marco Bua United Kingdom
David Marín United Kingdom
Malin Hultcrantz United States
Jeff H. Lipton Canada
Yousif Matloub United States
Md Ariful Haque relative to Fausto Castagnetti Italy Fausto Castagnetti's profile →
Citations per field
00.5×1.5×
Fausto Castagnetti · 1×
Citations per year

Countries citing papers authored by Md Ariful Haque

Since Specialization
Citations

This map shows the geographic impact of Md Ariful Haque's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Md Ariful Haque with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Md Ariful Haque more than expected).

Fields of papers citing papers by Md Ariful Haque

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Md Ariful Haque. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Md Ariful Haque. The network helps show where Md Ariful Haque may publish in the future.

Co-authors

The 25 scholars most cited alongside Md Ariful Haque, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Md Ariful Haque Line = papers co-authored together Md Ariful Haque links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 75 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
New England Journal of Medicine ·Giuseppe Saglio, Dong‐Wook Kim, Surapol Issaragrisil, P. Le Coutre, Gabriel Étienne, Clarisse Lobo, Ricardo Pasqüini, Richard E. Clark, Andreas Hochhaus, Timothy P. Hughes, Neil J. Gallagher, Albert Hoenekopp, Mei Dong, Md Ariful Haque, Richard A. Larson, Hagop M. Kantarjian
Hit paper breakdown →		20101182
2
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Blood ·Hagop M. Kantarjian, Francis J. Giles, Norbert Gattermann, Kapil N. Bhalla, Giuliana Alimena, Francesca Palandri, Gert J. Ossenkoppele, Franck-Emmanuel Nicolini, Stephen G. O’Brien, Mark R. Litzow, Ravi Bhatia, Francisco Cervantes, Md Ariful Haque, Yaping Shou, Debra Resta, Aaron Weitzman, Andreas Hochhaus, Philipp le Coutre
Hit paper breakdown →		2007540
3
Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Journal of Clinical Oncology ·Timothy P. Hughes, Giuseppe Saglio, Susan Branford, Simona Soverini, Dong‐Wook Kim, Martin C. Müller, Giovanni Martinelli, Jörge E. Cortes, Lan Beppu, Enrico Gottardi, Dong‐Ho Kim, Philipp Erben, Yaping Shou, Md Ariful Haque, Neil J. Gallagher, Jerald P. Radich, Andreas Hochhaus
2009236
4
Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib
Journal of Clinical Oncology ·Susan Branford, Dong‐Wook Kim, Simona Soverini, Md Ariful Haque, Yaping Shou, Richard C. Woodman, Hagop M. Kantarjian, Giovanni Martinelli, Jerald P. Radich, Giuseppe Saglio, Andreas Hochhaus, Timothy P. Hughes, Martin C. Müller
201274
5
Financial threat, hardship and distress predict depression, anxiety and stress among the unemployed youths: A Bangladeshi multi-city study
Journal of Affective Disorders ·Mohammed A. Mamun, Shaila Akter, Imran Hossain, Mohammad Thanvir Hasan Faisal, Md Atikur Rahman, Ahamedul Arefin, Imtiaz Ali Khan, Lukman Hossain, Md Ariful Haque, Sahadat Hossain, Moazzem Hossain, Md. Tajuddin Sikder, Kağan Kırcaburun, Mark D. Griffiths
202058
6
ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
Blood ·Timothy P. Hughes, Andreas Hochhaus, Giuseppe Saglio, Dong‐Wook Kim, Saengsuree Jootar, Philipp D. le Coutre, Josy Reiffers, Ricardo Pasqüini, Clarisse Lobo, Richard E. Clark, Neil J. Gallagher, Albert Hoenekopp, Md Ariful Haque, Richard A. Larson, Hagop M. Kantarjian
201037
7
Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib
Journal of Clinical Oncology ·Francis J. Giles, Richard A. Larson, Hagop M. Kantarjian, Philipp le Coutre, Francesca Palandri, Md Ariful Haque, Neil J. Gallagher, Oliver G. Ottmann
200835
8
Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CMLCP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study.
Blood ·Hagop M. Kantarjian, Francis J. Giles, Kapil N. Bhalla, Richard A. Larson, Norbert Gattermann, Oliver G. Ottmann, Md Ariful Haque, Neil J. Gallagher, Michele Baccarani, Philipp D. le Coutre
200833
9
Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial
Blood ·Giuseppe Saglio, Dong-Wook Kim, Surapol Issaragrisil, Philipp D. le Coutre, Josy Reiffers, Clarisse Lobo, Ricardo Pasqüini, Richard E. Clark, Timothy P. Hughes, Andreas Hochhaus, Neil J. Gallagher, Albert Hoenekopp, Mei Dong, Md Ariful Haque, Hagop M. Kantarjian, Richard A. Larson
200928
10
Nilotinib in Patients (pts) with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib.
Blood ·Oliver G. Ottmann, Richard A. Larson, Hagop M. Kantarjian, Philipp le Coutre, Michele Baccarani, Md Ariful Haque, Neil J. Gallagher, Francis J. Giles
200727
11
Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study
Blood ·Philipp D. le Coutre, Francis J. Giles, Andreas Hochhaus, Jane F. Apperley, Gert J. Ossenkoppele, Md Ariful Haque, Neil J. Gallagher, Michele Baccarani, Jörge E. Cortes, Hagop M. Kantarjian
200824
12
Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study
Journal of Clinical Oncology ·Philipp D. le Coutre, F. Giles, Andreas Hochhaus, Jane F. Apperley, G. J. Ossenkoppele, Md Ariful Haque, Neil J. Gallagher, Michele Baccarani, Jörge E. Cortes, Hagop M. Kantarjian
200924
13
Nilotinib Is Highly Active and Safe in Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Patients with Imatinib-Resistance or Intolerance.
Blood ·Hagop M. Kantarjian, Andreas Hochhaus, Jörge E. Cortes, Giovanni Martinelli, Kapil N. Bhalla, Francis J. Giles, Gert J. Ossenkoppele, Norbert Gattermann, Md Ariful Haque, Neil J. Gallagher, Michele Baccarani, Philipp le Coutre
200723
14
Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy.
PubMed ·M Shahidullah, Md Ariful Haque, Mohammed Rafiqul Islam, Andleeb Rizvi, Sultana N, Berlinson MIa, Muhammad Ajaz Hussain
201119
15
A Phase II Study of Nilotinib A Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Accelerated Phase (AP).
Blood ·Hagop M. Kantarjian, Norbert Gattermann, Andreas Hochhaus, Richard A. Larson, Teresa Rafferty, Aaron Weitzman, Md Ariful Haque, Francis J. Giles, S G O'Brien, Philipp le Coutre
200618
16
Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results
Journal of Clinical Oncology ·Hagop M. Kantarjian, Francis J. Giles, Andreas Hochhaus, Kapil N. Bhalla, G. J. Ossenkoppele, Norbert Gattermann, Md Ariful Haque, Neil J. Gallagher, Fausto Castagnetti, Philipp le Coutre
200818
17
Responses and Disease Progression in CML-CP Patients Treated with Nilotinib after Imatinib Failure Appear To Be Affected by the BCR-ABL Mutation Status and Types.
Blood ·Timothy P. Hughes, Giuseppe Saglio, Giovanni Martinelli, Dong‐Wook Kim, Simona Soverini, Martin Mueller, Md Ariful Haque, Neil J. Gallagher, Yaping Shou, Jerald P. Radich, Susan Branford, Andreas Hochhaus
200717
18
Nilotinib in Patients (pts) with Philadelphia Chromosome-Positive (Ph+) Chronic Myelogenous Leukemia in Blast Crisis (CML-BC) Who Are Resistant or Intolerant to Imatinib.
Blood ·Francis J. Giles, Richard A. Larson, Hagop M. Kantarjian, Philipp le Coutre, Michele Baccarani, Md Ariful Haque, Neil J. Gallagher, Oliver G. Ottmann
200717
19
Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP)
Journal of Clinical Oncology ·Elias Jabbour, Andreas Hochhaus, Philipp le Coutre, G. Rosti, Kapil N. Bhalla, Md Ariful Haque, Neil J. Gallagher, Francis J. Giles, Jörge E. Cortes, Hagop M. Kantarjian
200816
20
Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or -intolerance: Update of a phase II study
Journal of Clinical Oncology ·Philipp le Coutre, Francis J. Giles, Jane F. Apperley, Oliver G. Ottmann, Richard A. Larson, Md Ariful Haque, Neil J. Gallagher, G. Rosti, Jörge E. Cortes, Hagop M. Kantarjian
200815

About Md Ariful Haque

Md Ariful Haque is a scholar working on Genetics, Hematology, Rheumatology, Surgery and Epidemiology, having authored 75 papers that have together received 2.6k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (33 papers), Chronic Lymphocytic Leukemia Research (33 papers), Eosinophilic Disorders and Syndromes (14 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers), Acute Lymphoblastic Leukemia research (4 papers), Surgical Simulation and Training (2 papers), Sarcoma Diagnosis and Treatment (2 papers) and COVID-19 and Mental Health (2 papers). The work is most often cited by research in Hematology (2.3k citations), Genetics (2.0k citations), Rheumatology (1.4k citations), Oncology (313 citations) and Pathology and Forensic Medicine (177 citations). Md Ariful Haque has collaborated with scholars based in China, United States and Germany. Frequent co-authors include Hagop M. Kantarjian, Andreas Hochhaus, Neil J. Gallagher, Timothy P. Hughes, Giuseppe Saglio, Dong‐Wook Kim, Richard A. Larson, Albert Hoenekopp, Clarisse Lobo and Richard E. Clark. Their work appears in journals such as Blood, Journal of Clinical Oncology, International Journal of Surgery, Medicine and Journal of Affective Disorders.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fausto CastagnettiBreakdown of academic impact, for papers by Valentín García‐GutiérrezBreakdown of academic impact, for papers by Sebastian KreilBreakdown of academic impact, for papers by Jamshid S. KhorashadBreakdown of academic impact, for papers by David T YeungBreakdown of academic impact, for papers by Marco BuaBreakdown of academic impact, for papers by David MarínBreakdown of academic impact, for papers by Malin HultcrantzBreakdown of academic impact, for papers by Jeff H. LiptonBreakdown of academic impact, for papers by Yousif Matloub